MEDIPHARM ANDERLECHT

Active

Private limited companyfounded 2023active for 3 yearsProvencewandelwegen 40, 1140 Evere, BelgiumKBO/BCE: BE 0803.351.426

Summary

The computed 12-month bankruptcy probability of MEDIPHARM ANDERLECHT is 2.1% (moderate). The 2025 annual accounts show equity of €17,978 and a net result of €32,003. Equity remains stable across the filed financial years (±1.8% per year). Its solvency ranks better than 26% of 22,650 sector peers (NACE 47, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

MEDIPHARM ANDERLECHTActiveChecked score 54/100

Risk analysis Report Compare

Directors

1 director, no change since 2023

CHEAIB Samer

Director (not named in the articles) · since 03-07-2023

Current

Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

1 person since 2023, 1 in office

All 1 In office 1

Board

Mandates per person, with start and end dates
Name	Functions and periods
CHEAIB Samer	Director (not named in the articles), from 03-07-2023 to date

See the board, name and registered office on a given date →

Owners and capital

Capital and shareholders

Shareholders according to the deeds

At incorporation act of 03-07-2023 ↗

CHEAIB Samer 1,000 shares (100%) · €3,000 in cash

The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years

03-07-2023 Incorporation · €3,000 · 1,000 shares